Bill Snyder

April 23, 2020

Health workers sought for hydroxychloroquine study

Health care workers at Vanderbilt University Medical Center at high risk of exposure to COVID-19 can participate in a randomized, controlled clinical trial testing the effectiveness of the drug hydroxychloroquine (HCQ) in preventing infection.

By Bill Snyder
April 15, 2020

Faculty Awards honor teaching, research, clinical excellence

Vanderbilt University School of Medicine has announced the 2020 faculty awards for Excellence in Teaching, Outstanding Contributions to Research and Extraordinary Performance of Clinical Service.

By Bill Snyder
April 8, 2020

Self-care crucial for providers during pandemic

High levels of stress and anxiety can be debilitating, especially for health care providers on the front lines of the COVID-19 pandemic. But there are ways they can protect themselves and their ability to provide the best and most compassionate care.

By Bill Snyder
April 8, 2020

Vanderbilt University Medical Center and AstraZeneca join forces to identify potential COVID-19 treatments

Vanderbilt University Medical Center and the global biopharmaceutical company AstraZeneca have joined forces to identify candidates for antibody-based treatments that could protect people exposed to the 2019 novel coronavirus disease, COVID-19.

By Bill Snyder
April 6, 2020

VUMC team aids development of potential antiviral drug for COVID-19

Researchers at Vanderbilt University Medical Center are playing a key role in the development of a potential new antiviral drug to treat COVID-19.

By Bill Snyder
April 2, 2020

Study aims to shield health workers from COVID-19 infection

VUMC is playing a key role in a national effort to establish a registry of U.S. health care workers and test whether the anti-malarial drug hydroxychloroquine (HCQ) will protect them, their patients and their families from COVID-19.

By Bill Snyder
March 23, 2020

Researchers developing potential coronavirus antibody therapies

Vanderbilt University Medical Center is teaming up with academic, governmental and corporate partners in an unprecedented, fast-tracked global effort to develop antibody-based treatments to protect people exposed to the 2019 novel coronavirus disease, COVID-19.
By Bill Snyder
March 19, 2020

Blocking stress-induced relapse

Danny Winder and colleagues are teasing apart the actions of neurotransmitter receptors in a brain region linked to anxiety and addiction, with a goal of finding treatments for substance use disorders.
By Bill Snyder
March 18, 2020

Ibuprofen and COVID-19: a doctor’s guidance

Last week, France’s health ministry urged people who have been infected by the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) to avoid taking over-the- counter nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, naproxen and aspirin because they might increase the severity of the infection.
By Bill Snyder
March 18, 2020

UC Berkeley’s Doudna named to receive Vanderbilt Prize

Jennifer Doudna, PhD, who led development of the revolutionary genome editing technology known as CRISPR-Cas9, is the recipient of the 2020 Vanderbilt Prize in Biomedical Science, officials at Vanderbilt University Medical Center announced this week.
By Bill Snyder
March 12, 2020

Clinical investigation society lauds Vanderbilt scientists

Five faculty members of Vanderbilt University School of Medicine are among 80 physician-scientists who will be inducted this year into the American Society for Clinical Investigation (ASCI), an elite honor society of physician-scientists from the upper ranks of academic medicine and industry. They are:
By Bill Snyder
March 4, 2020

Neurotransmitter expert Amara set for March 12 Discovery Lecture

Susan Amara, PhD, scientific director of the Intramural Research Program at the National Institute of Mental Health (NIMH) and an expert on the biology of neurotransmitter transporters, will deliver the next Flexner Discovery Lecture on Thursday, March 12.
By Bill Snyder